Also known as MED-18897, MEDI8897
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).